Risk Evaluation and Education of Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging

Risk Evaluation and Education of Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging

Brief description of study

REVEAL-SCAN is a multi-site study funded by the National Institutes of Health, with support from the Alzheimer’s Association. The purpose of the study is to understand how people respond to learning their risk of developing Alzheimer’s disease dementia. Each participant in REVEAL-SCAN receives a personalized estimate of his or her risk of developing Alzheimer’s disease dementia by the age of 85. This risk is based on current age, race, gender, and family history of Alzheimer’s disease dementia. Participants will have amyloid neuroimaging, also known as an amyloid brain scan, or an amyloid PET scan.

Detailed description of study

Understanding how people respond to learning their risk of developing Alzheimer’s disease (AD) dementia and amyloid PET scan results will help researchers and clinicians more effectively communicate with patients and research participants about AD dementia risk and the role of amyloid. All participants will be followed for 6-7 months after learning their estimated risk of developing AD dementia by age 85. Half of the participants will learn their amyloid scan result along with their risk estimate, and the other half will learn the scan result 7 months later. Participants are randomly assigned to one of these two groups. REVEAL-SCAN is not a treatment study. You will not receive any medication in this study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's disease,Memory loss,Cognition Disorders,Dementia,Memory loss,Multi-infarct dementia,healthy Volunteers,healthy subjects,Healthy,healthy controls,aging,Healthy volunteer,Multi-infarct dementia,healthy,healthy volunteer,healthy volunteers,healthy subjects,healthy,healthy controls,aging,alzheimer's disease,healthy controls,multi infarct dementia,memory loss,dementia,amyloid
  • Age: Between 65 Years - 80 Years
  • Gender: All


Updated on 08 Jul 2023. Study ID: 825741

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center